… excipients listed in section 6.1.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Amias with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR< 60ml/min/1.73m2) (see sections 4.5 and 5.1).
Identical in all 3 labels. Surrounding text shown from Neon Healthcare Ltd.
… andesartan cilexetil or to any of the excipients listed in section 6.1.
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
• Severe hepatic impairment and/or cholestasis.
• The concomitant use of Candesartan Cilexetil with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
• Children aged below 1 year (see section 5.3).
Identical in both labels. Surrounding text shown from Sandoz Limited.
… he excipientslisted in section 6.1
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Candesartan with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see Sections 4.5 and 5.1).
Identical in both labels. Surrounding text shown from Aurobindo Pharma - Milpharm Ltd..
… cipients listed in section 6.1.
Second and third trimester of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Candesartan cilexetil with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Identical in both labels. Surrounding text shown from Krka UK Ltd.
… he excipientslisted in section 6.1
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Candesartan with aliskiren-containing products is contra-indicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see Sections 4.5 and 5.1).